| 47.28 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 55.29 | 1-year : | 55.36 |
| Resists | First : | 47.33 | Second : | 47.4 |
| Pivot price | 47.27 | |||
| Supports | First : | 47.24 | Second : | 39.3 |
| MAs | MA(5) : | 47.27 | MA(20) : | 47.27 |
| MA(100) : | 47.17  |
MA(250) : | 45.19 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 24.9 | D(3) : | 24.9 |
| RSI | RSI(14): 54.7 | |||
| 52-week | High : | 47.4 | Low : | 33.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PPD ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
Tue, 26 Mar 2024
Global Healthcare CRO Services Market Report 2024-2028 & 2033 Featuring Profiles of Laboratory Corporation of ... - Yahoo Finance
Wed, 28 Feb 2024
Medidata and Thermo Fisher Scientific's PPD Clinical Research Business Collaborate to Accelerate Clinical Trials ... - Business Wire
Tue, 06 Feb 2024
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 - BioSpace
Thu, 21 Dec 2023
Thermo Fisher Scientific's PPD Clinical Research Business Selected by BARDA to Support Phase II Platform Clinical ... - Business Wire
Thu, 27 Jul 2023
Zuranolone improves PPD symptoms in Phase III trial - Clinical Trials Arena
Sun, 09 Jul 2023
PPD - Carlyle
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 351 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 22.5 (%) |
| Held by Institutions | 79.4 (%) |
| Shares Short | 15,380 (K) |
| Shares Short P.Month | 16,200 (K) |
| EPS | 1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.22 |
| Profit Margin | 6.1 % |
| Operating Margin | 11.3 % |
| Return on Assets (ttm) | 6.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 26.5 % |
| Gross Profit (p.s.) | 8.53 |
| Sales Per Share | 16.73 |
| EBITDA (p.s.) | 2.75 |
| Qtrly Earnings Growth | 2123.1 % |
| Operating Cash Flow | 569 (M) |
| Levered Free Cash Flow | 469 (M) |
| PE Ratio | 47.27 |
| PEG Ratio | 0 |
| Price to Book value | -39.08 |
| Price to Sales | 2.82 |
| Price to Cash Flow | 29.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|